DIABETIC NEPHROPATHY: Could problems with bardoxolone methyl have been predicted?

    loading  Checking for direct PDF access through Ovid

Abstract

Bardoxolone methyl showed promising results in initial studies in patients with type 2 diabetic kidney disease, but a phase III trial was terminated early in October 2012 due to adverse effects and increased mortality. Can adverse findings of analogues of bardoxolone methyl in an animal model explain the human findings?

Related Topics

    loading  Loading Related Articles